Information Mediary Corp. and Adherence Partner to Launch Revolutionary Digital MMAS Integration for Medication Adherence
Information Mediary Corp. and Adherence Partner to Launch Revolutionary Digital MMAS Integration for Medication Adherence
Information Mediary Corp (IMC) and Adherence have collaborated to introduce a digitized Morisky Medication Adherence Scale (MMAS), revolutionizing medication adherence management.
Information Mediary Corp（IMC）和Alistence合作推出了數字化的莫里斯基藥物依從性量表（MMAS），徹底改變了藥物依從性管理。
NEW YORK, May 6, 2024 /PRNewswire/ -- Information Mediary Corp (IMC) and Adherence have collaborated to introduce a digitized Morisky Medication Adherence Scale (MMAS), revolutionizing medication adherence management. This innovative solution signifies a significant advancement in precision and efficiency in patient care.
紐約，2024年5月6日 /PRNewswire/ — Information Mediary Corp（IMC）和Alistence合作推出了數字化的莫里斯基藥物依從性量表（MMAS），徹底改變了藥物依從性管理。這種創新的解決方案標誌着患者護理精度和效率的顯著提高。
The Morisky scale plays a crucial role in ensuring patients adhere to their prescribed medications, directly impacting treatment outcomes by preventing disease progression, reducing complications, and enhancing overall health outcomes.
莫里斯基量表在確保患者遵守處方藥方面起着至關重要的作用，通過防止疾病進展、減少併發症和改善整體健康狀況直接影響治療結果。
Recognized as the gold standard for assessing medication adherence, the MMAS-4 and MMAS-8 have been referenced in over 31,298 academic journals.
MMAS-4 和 MMAS-8 被公認爲評估藥物依從性的黃金標準，已被超過 31,298 份學術期刊引用。
This new partnership combines IMC's cutting-edge dose analytics with Adherence's expertise to create a solution that integrates patient-reported MMAS data with objective adherence information. Through this collaboration, IMC will seamlessly integrate MMAS with the CertiScan Adherence Insight Platform, eCAP, and Med-ic, providing partners with a comprehensive suite of tools for advanced adherence monitoring and improved patient outcomes.
這種新的合作伙伴關係將IMC的尖端劑量分析與依從性的專業知識相結合，創建了一種將患者報告的MMAS數據與客觀依從性信息相結合的解決方案。通過此次合作，IMC將把MMAS與CertiScan依從性洞察平台、eCAP和Med-IC無縫整合，爲合作伙伴提供一套全面的工具，用於高級依從性監測和改善患者預後。
A key focus of this partnership is the development of APIs for third-party platform integration. This initiative will enable industry partners to leverage the benefits of this innovative solution across various healthcare settings.
這種合作關係的主要重點是開發用於第三方平台集成的API。該計劃將使行業合作伙伴能夠在各種醫療保健環境中利用這種創新解決方案的優勢。
Dean Brotzel, CTO of IMC, emphasized, "The digital MMAS integration marks a significant milestone in medication adherence monitoring. By leveraging combined data sources, we are transforming the approach healthcare providers and patients take towards medication adherence."
IMC首席技術官迪恩·布羅策爾強調說：“數字化MMAS集成標誌着藥物依從性監測領域的一個重要里程碑。通過利用綜合數據源，我們正在改變醫療保健提供者和患者在堅持用藥方面採取的方法。”
For media inquiries or more information on the groundbreaking collaboration between IMC and Adherence, please contact [email protected] or [email protected]
如需媒體垂詢或有關 IMC 與 Afference 之間開創性合作的更多信息，請聯繫 [email protected] 或 [email protected]
About Information Mediary Corp (IMC): IMC is at the forefront of developing smart packaging solutions that integrate cutting-edge technology to enhance patient safety, medication adherence, and healthcare outcomes.
關於信息媒體公司（IMC）： IMC處於開發智能包裝解決方案的最前沿，該解決方案整合了尖端技術，以增強患者安全、藥物依從性和醫療保健結果。
IMC's Med-ic is the only Smart Dose blister ever submitted with a FDA priority review resulting in a blockbuster drug approval. Over a million smart Med-ic blisters have been used over the past few years to gather valuable adherence data from over 20 million doses in pivotal clinical trials with customers such as AbbVie and Merck. InformationMediary.com
IMC的Med-ic是有史以來唯一一款獲得美國食品藥品管理局優先審查的智能劑量泡罩，該藥品獲得了轟動一時的批准。在過去的幾年中，在與艾伯維和默沙東等客戶進行的關鍵臨床試驗中，已使用超過一百萬個智能Med-ic泡罩來收集超過2000萬劑量的寶貴依從性數據。Informediary.com
About Adherence: The MMAS (Morisky Medication Adherence Scale), developed by Dr. Donald Morisky and several co-authors, is a 4 and 8 item self-report questionnaire that evaluates medication adherence by probing behaviors like medication forgetting or discontinuation. The MMAS is widely applied in healthcare research and clinical practice, aiding in the identification of patients at risk of non-adherence and guiding the customization of adherence interventions.
關於依從性： 由唐納德·莫里斯基博士和幾位合著者開發的MMAS（莫里斯基藥物依從性量表）是一份4項和8項的自我報告問卷，通過探測遺忘用藥或停藥等行爲來評估藥物依從性。MMAS 廣泛應用於醫療保健研究和臨床實踐，有助於識別存在不依從風險的患者，並指導依從性干預措施的定製。
Adherence serves as the catalyst with pharmaceutical firms, telehealth initiatives, and IT platforms seamlessly integrating MMAS into their systems and procedures. MMAS is intricately woven into defined protocols for standards of care, endpoints and outcome measures in clinical trials, medication therapy management, and patient intake processes. adherence.cc
依從性是製藥公司、遠程醫療計劃和IT平台將MMA無縫集成到其系統和程序中的催化劑。MMAS 錯綜複雜地融入了臨床試驗、藥物治療管理和患者入院過程中的護理標準、終點和結果衡量標準的既定協議中。adherence.cc
Press contact:
新聞聯繫人：
Joanne Watters
6137458400
喬安妮·沃特斯
6137458400
SOURCE Information Mediary Corp.
來源信息 Mediary Corp.
譯文內容由第三人軟體翻譯。